**Study for Multiple Myeloma Patients**
This study is testing a drug called *Belantamab Mafodotin* on people with a type of cancer called Multiple Myeloma that has come back or hasn't responded to treatment. Multiple Myeloma affects a part of blood cells called B-cells. The study will see how this drug works alone and with other cancer drugs in adults.
**Key Points:**
- **Participation Length:** The study has different parts and can last for varied times depending on which part you join.
- **Eligibility:** You must be 18 or older with a confirmed Multiple Myeloma diagnosis and have tried at least 3 other treatments before.
- **Study Visits and Risks:** Participants will need to visit the study site regularly for tests and treatment. There are certain health criteria you must meet, and some past treatments may not be allowed.
Remember, this is a chance to try new treatments, but there are risks and requirements involved. If you're interested, discuss with your doctor to see if you qualify and if this is a good option for you.
How understandable was the trial content above?
Hard to understand
Easy to understand